BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34330018)

  • 1. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity.
    Hoffmann FS; Kuhn PH; Laurent SA; Hauck SM; Berer K; Wendlinger SA; Krumbholz M; Khademi M; Olsson T; Dreyling M; Pfister HW; Alexander T; Hiepe F; Kümpfel T; Crawford HC; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    J Immunol; 2015 Jan; 194(2):542-52. PubMed ID: 25505277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
    Laurent SA; Hoffmann FS; Kuhn PH; Cheng Q; Chu Y; Schmidt-Supprian M; Hauck SM; Schuh E; Krumbholz M; Rübsamen H; Wanngren J; Khademi M; Olsson T; Alexander T; Hiepe F; Pfister HW; Weber F; Jenne D; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
    Nat Commun; 2015 Jun; 6():7333. PubMed ID: 26065893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
    Schuh E; Musumeci A; Thaler FS; Laurent S; Ellwart JW; Hohlfeld R; Krug A; Meinl E
    J Immunol; 2017 Apr; 198(8):3081-3088. PubMed ID: 28283566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
    Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
    MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
    Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
    Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
    Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
    Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
    Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.
    Miao YR; Thakkar K; Cenik C; Jiang D; Mizuno K; Jia C; Li CG; Zhao H; Diep A; Xu Y; Zhang XE; Yang TTC; Liedtke M; Abidi P; Leung WS; Koong AC; Giaccia AJ
    J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35881112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Features of Isoforms of Human Soluble TACI.
    Fichtner ML; Rübsamen H; Smolle M; Schaller J; Feederle R; Bültmann A; Kümpfel T; Schneider P; Thaler FS; Meinl E
    J Immunol; 2023 Jul; 211(2):199-208. PubMed ID: 37272840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble B-cell maturation antigen in multiple myeloma.
    Costa BA; Ortiz RJ; Lesokhin AM; Richter J
    Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J; Veyrune JL; De Vos J; Klein B
    BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
    Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
    Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
    Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
    Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.